Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-AP-ES vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Reserpine: 50-100h (terminal); hydralazine: 2-8h (slow acetylators 4-8h, fast 2-4h); hydrochlorothiazide: 6-15h. Context: reserpine's long t½ accounts for prolonged effects; hydralazine requires dose adjustment for acetylator status.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Reserpine: extensively metabolized in liver; Hydralazine: hepatic acetylation (N-acetyltransferase); Hydrochlorothiazide: not metabolized, excreted unchanged.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: 30-40% unchanged reserpine; 60-70% as metabolites (hydralazine: 50% renal, 15% fecal; hydrochlorothiazide: 95% renal unchanged).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Reserpine: 40% bound (albumin); hydralazine: 87% bound; hydrochlorothiazide: 40-68% bound (albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Reserpine: 6 L/kg; hydralazine: 1.6 L/kg; hydrochlorothiazide: 0.8 L/kg. Clinical meaning: reserpine extensive tissue distribution (fat, brain); hydralazine moderate; thiazide limited to extracellular fluid.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Reserpine: 50% oral; hydralazine: 30-50% oral; hydrochlorothiazide: 65-75% oral.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Hydrochlorothiazide: Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-50 m L/min: reduce dose of hydrochlorothiazide to 12.5 mg daily; consider using individual components. Reserpine and hydralazine: no specific GFR-based adjustment, but use with caution if severe renal impairment.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Reserpine and hydralazine are contraindicated in severe hepatic impairment. For Child-Pugh A or B: no specific dose adjustment but monitor closely. For Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended for pediatric use due to lack of safety and efficacy data. Use individual components with appropriate weight-based dosing if needed.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate with one tablet orally once daily. Titrate slowly due to increased risk of hypotension, electrolyte disturbances, and central nervous system effects. Monitor renal function and electrolytes closely.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Reserpine: May cause depression, peptic ulcer activation.,Hydralazine: Drug-induced lupus, peripheral neuritis (pyridoxine deficiency), tachycardia.,Hydrochlorothiazide: Electrolyte imbalance, hyperuricemia, photosensitivity.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to any component,History of depression (reserpine),Severe renal impairment (hydralazine, hydrochlorothiazide),Anuria (hydrochlorothiazide)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid foods high in sodium to prevent bloating and counteract diuretic effect. Excessive potassium intake (e.g., salt substitutes, bananas, oranges) may be needed if hypokalemia is present, but monitor potassium levels. Grapefruit juice may alter absorption; avoid large amounts. Alcohol increases risk of hypotension and sedation; avoid concurrent use.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
SER-AP-ES is a combination product containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine: crosses placenta, animal studies show fetal abnormalities (skeletal and CNS) in high doses; first trimester risk uncertain, second/third trimester associated with neonatal respiratory depression, bradycardia, hypothermia. Hydralazine: animal studies show cleft palate, skeletal malformations; human data limited; risk not excluded. Hydrochlorothiazide: associated with neonatal thrombocytopenia, electrolyte disturbances, and possibly fetal or neonatal jaundice; second/third trimester use may cause fetal hypoxia and placental insufficiency. Overall, avoid in pregnancy unless benefit outweighs risk; first trimester highest risk.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Reserpine: excreted into breast milk; M/P ratio ~0.5; may cause galactorrhea, breast engorgement, or adverse effects in infant (drowsiness, nasal congestion). Hydralazine: present in breast milk in low amounts (M/P ratio ~1); considered compatible but monitor infant for hypotension. Hydrochlorothiazide: excreted in breast milk in low concentrations (M/P ratio ~0.5); may suppress lactation and cause electrolyte imbalance in infant. Use caution; avoid if possible or monitor infant.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Pharmacokinetic changes: increased plasma volume and renal clearance may reduce drug concentrations; hydralazine undergoes acetylation (polymorphic), may require dose increase. Reserpine: no data, but similar adjustments not typically recommended. Hydrochlorothiazide: reduced efficacy due to volume expansion; avoid in pregnancy-induced hypertension. In severe hypertension, hydralazine may be used IV with cautious titration; oral adjustments: start low, titrate based on response.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
SER-AP-ES is a combination antihypertensive containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine depletes catecholamines centrally and peripherally; may cause depression, nasal congestion, and bradycardia. Hydralazine is a direct vasodilator; can cause drug-induced lupus-like syndrome, especially in slow acetylators. Hydrochlorothiazide is a thiazide diuretic; monitor for hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with depression, peptic ulcer disease, or history of SLE. Titrate slowly due to reserpine's cumulative effect.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not stop suddenly as this may cause rapid rise in blood pressure.,Avoid over-the-counter cold or allergy medications without consulting your doctor.,Report symptoms of depression, mood changes, or suicidal thoughts immediately.,May cause dizziness or drowsiness; avoid driving until you know how this medication affects you.,Do not consume alcohol; it may increase side effects.,Monitor your blood pressure regularly and keep a log.,Stay hydrated but avoid excessive salt intake.,Report any unexplained fever, joint pain, or skin rash; may be signs of lupus-like reaction.,This medication may increase blood sugar; monitor if diabetic.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-AP-ES vs ALDOCLOR-150, answered by our medical review team.
SER-AP-ES is a Antihypertensive Combination that works by SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-AP-ES and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-AP-ES is: SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-AP-ES and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-AP-ES is classified as Category C. SER-AP-ES is a combination product containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine: crosses placenta, animal studies show fetal abnormalities (skeletal and CN. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.